Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours

Current Oncology

Volumn 21, Issue 6, 2014, Pages 309-317

  Raymond, E ^a   Faivre, S ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Cdd; Pancreatic net; Sunitinib

Indexed keywords

SUNITINIB;

ABDOMINAL PAIN; ANOREXIA; ASTHENIA; BLOOD CELL COUNT; CARDIOVASCULAR DISEASE; CONTINUOUS DAILY DOSING; DIARRHEA; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ERYTHEMA; FATIGUE; GASTROINTESTINAL TOXICITY; HAIR DISEASE; HAND FOOT SYNDROME; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; LIVER FUNCTION TEST; MEDICATION COMPLIANCE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN TOXICITY; STOMATITIS; THYROID FUNCTION; VOMITING;

EID: 84916205733     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1647     Document Type: Review

References (36)

1. Yao JC, Eisner MP, Leary C, et al.Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-500.
2. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (pnets): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-33.
3. Yao JC, Hassan M, Phan A, et al.One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
4. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92.
5. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 2011;4:29.
6. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-88.
7. Oberg K, Kvols L, Caplin M, et al.Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966-73.
8. Rinke A, Müller HH, Schade-Brittinger C, et al.Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid Study Group. J Clin Oncol 2009;27:4656-63.
9. Moertel CG, Johnson CM, McKusick MA, et al.The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
10. Baltogiannis G, Katsios C, Roukos DH. New target therapies for patients with neuroendocrine tumors of the pancreas. Expert Rev Gastroenterol Hepatol 2011;5:563-6.
11. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of vegf signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
12. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. vegf-a has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1:193-202.
13. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-45.
14. Fjällskog ML, Hessman O, Eriksson B, Janson ET. Upregulated expression of pdgf receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 2007;46:741-6.
15. Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-73.
16. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
17. Faivre S, Delbaldo C, Vera K, et al.Safety, pharmacokinetic, and antitumour activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
18. Pfizer Labs. Sutent-sunitinib malate capsule [prescribing information]. New York, NY: Pfizer Labs; 2011. [Available online at http://labeling.pfizer.com/showlabeling.aspx?id=607; cited September 29, 2014]
19. European Medicines Agency (ema). Sutent [Web resource]. London, UK: ema; 2013. [Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000687/human_med_001069.jsp&mid=WC0b01ac058001d124; cited January 16, 2012]
20. Mancuso MR, Davis R, Norberg SM, et al.Rapid vascular regrowth in tumors after reversal of vegf inhibition. J Clin Invest 2006;116:2610-21.
21. George S, Blay JY, Casali PG, et al.Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68.
22. Demetri GD, van Oosterom AT, Garrett CR, et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006;368:1329-38.
23. Motzer RJ, Hutson TE, Olsen MR, et al.Randomized phase ii trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30:1371-7.
24. Houk HE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357-71.
25. Barrios CH, Hernandez-Barajas D, Brown MP, et al.Phase ii trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012;118:1252-9.
26. Escudier B, Roigas J, Gillessen S, et al.Phase ii study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75.
27. Raymond E, Dahan L, Raoul JL, et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
28. Novello S, Scagliotti GV, Rosell R, et al.Phase ii study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-8.
29. Carr LL, Mankoff DA, Goulart BH, et al.Phase ii study of daily sunitinib in fdg-pet-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-8.
30. Kozloff M, Chuang E, Starr A, et al.An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010;21:1436-41.
31. Koeberle D, Montemurro M, Samaras P, et al.Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (sakk) and Swiss Association for the Study of the Liver (sasl) multicenter phase ii trial (sakk 77/06). Oncologist 2010;15:285-92.
32. Kulke MH, Lenz HJ, Meropol NJ, et al.Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10.
33. Grünwald V, Kalanovic D, Merseburger AS. Management of sunitinib-related adverse events: an evidence- and expertbased consensus approach. World J Urol 2010;28:343-51.
34. Ivanyi P, Winkler T, Ganser A, Reuter C, Grünwald V. Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch Arztebl Int 2008;105:232-7.
35. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. Ver. 1.2012. Fort Washington, PA: nccn; 2012. [Current version available online at: http://www.nccn.com/files/cancer-guidelines/breast/index.html; cited January 16, 2012]
36. Theou-Anton N, Faivre S, Dreyer C, Raymond E. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Saf 2009;32:717-34.